Trials / Conditions / Small Cell Lung Cancer Recurrent

Small Cell Lung Cancer Recurrent

9 registered clinical trials studyying Small Cell Lung Cancer Recurrent — 2 currently recruiting.

Status	Trial	Sponsor	Phase
Not Yet Recruiting	Toripalimab and JS004 Combined With Platinum-based Chemotherapy for Relapsed and Extensive-stage Small Cell Lu NCT06648200	Shanghai Pulmonary Hospital, Shanghai, China	Phase 2
Recruiting	Irinotecan Liposome Combined With Anlotinib as Second-line Regimen for SCLC NCT06258642	Fudan University	N/A
Active Not Recruiting	Debio 0123 in Combination With Carboplatin and Etoposide in Adult Participants With Small Cell Lung Cancer Tha NCT05815160	Debiopharm International SA	Phase 1
Terminated	KRT-232 in Subjects With Relapsed or Refractory Small Cell Lung Cancer NCT05027867	Kartos Therapeutics, Inc.	Phase 2
Unknown	Assessing Safety and Efficacy of Sintilimab and Metformin Combination Therapy in SCLC NCT03994744	Hunan Cancer Hospital	Phase 2
Completed	S1 Plus Anlotinib in Treating Patients With Refractory or Relapsed Small-cell Lung Cancer NCT03823118	Taizhou Hospital	Phase 2
Unknown	Sequential Hypofractionated Radiotherapy Followed by Anti-PD-L1 Atezolizumab for SCLC NCT03262454	National Cancer Center, Korea	Phase 2
Terminated	Temozolomide in Patients Affected by Relapsed Sensitive or Refractory Small Cell Lung Cancer With MGMT Methyla NCT02477813	Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS	Phase 2
Completed	BIBF 1120 as Second Line Treatment for Small Cell Lung Cancer NCT01441297	Ji-youn Han	Phase 2